
Please try another search
Intuitive Surgical Inc. (NASDAQ:ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20. Last quarter, the company’s earnings exceeded the Zacks Consensus Estimate by 17.63%. Also, the company delivered an average beat of 14.44% in the trailing four quarters.
Let’s see how things are shaping up for Intuitive Surgical prior to this announcement.
Factors at Play
We believe that the growing adoption of Intuitive Surgical’s da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a key catalyst. Earlier, da Vinci procedures increased approximately 18% year over year in the first quarter of 2017. For the second quarter, the company expects procedure growth rate to slow down a bit outside the U.S. The company anticipates full-year 2017 procedure growth within 12% to 14%. Full-year 2017 gross profit margin is expected in the upper end of the range of 69% to 71% of net revenue.
Moreover, rising procedural volumes outside the U.S., particularly in Europe, fortifies the company’s market position. In fact, the integrated Table Motion product line has gained significant traction within a short span of time and is likely to boost the company’s top line in the to-be-reported quarter. Meanwhile, increased spending on product development and higher investments in expanding the company’s footprint in international markets are prudent moves to drive long-term growth in our view.
We note that Intuitive Surgical outperformed the Zacks Medical Instruments sub-industry in the last one year. While the stock has returned 41.11%, the sub-industry has gained only 10.08%.
Earnings Whispers
Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: Intuitive Surgical’s Earnings ESP is 0.00% since both the Most Accurate estimate and the Zacks Consensus Estimate stand at $4.86. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Intuitive Surgical has a Zacks Rank #3. Though a favorable Zacks Rank increases the predictive power of ESP, the company’s ESP of 0.00% makes surprise prediction difficult.
Also, we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter:
Thermo Fisher Scientific Inc. (NYSE:TMO) has an Earnings ESP of 0.44% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Dextera Surgical Inc. (NASDAQ:DXTR) has an Earnings ESP of +9.09% and holds a Zacks Rank #2.
Telefex Incorporated (NYSE:TFX) has an Earnings ESP of +1.06% and carries a Zacks Rank #2.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
The markets have been sluggish this week as investors hope for a jolt later in the week when AI juggernaut NVIDIA Corporation (NASDAQ:NVDA) reports fourth quarter and year-end...
On Friday, a wave of selling pressure swept across the US equity markets, leaving a trail of losses. The S&P 500 closed down 1.7%, the DOW slid 1.69%, and the NASDAQ tumbled a...
Palantir remains highly valued with a 460x P/E ratio and a 42.5x P/B ratio, far above its peers. The stock's beta of 2.81 signals high volatility, meaning sharp moves in both...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.